PubMed Health⌕ Search

Biomedical subjects

H Rowe

Publications and source records attributed to H Rowe.

36 records · Page 2Linked to original sources

Clinical pharmacology of nabilone, a cannabinol derivative.

Nabilone is a modified cannabinol derivative with central nervous system activity. Administration of nabilone in single doses of 1 to 5 mg results in dose-related pharmacologic effects in man. One and 2.5 mg doses of nabilone induced relaxant and sedative effects in all subjects. No euphoria, dry mouth, tachycardia, or postural hypotension was seen after 1 mg, minimal effects were seen after 2.5 mg, and marked effects were seen after 5 mg. Effects were evident within 60 to 90 min and persisted for 8 to 12 hr. Nabilone produced no significant tachycardia. There were no changes in supine blood pressure; however, marked postural hypotension occurred after the 5-mg dose. The administration of nabilone at doses of 1 mg or 2 mg two times daily resulted in euphoria and dry mouth during the first two days of drug; thereafter tolerance developed to these effects but there was no apparent decrease in relaxation. Subjects challenged with a single 5-mg dose of nabilone showed a 66% reduction in symptoms and signs after the 7-day drug period compared to that of the same dose after 1 wk of placebo. Comparison of nabilone with other cannabinol derivatives suggests that some of the undesirable pharmacologic effects can be separated within the group.

Adult↗

Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol.

A comparison of the psychologic and physiologic effects of intravenously administered Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-Delta(9)-THC) was carried out in nine casual marihuana smokers. A marked tachycardia and psychologic "high" occurred within 3-5 min after the i.v. administration of 11-OH-Delta(9)-THC (1 mg) to all subjects. In contrast, the peak psychologic "high" was delayed 10-20 min after the i.v. administration of Delta(9)-THC (1 mg). There was some individual variation in response among subjects. Psychologic effects correlated well with plasma levels of unchanged [(3)H]11-OH-Delta(9)-THC. About 75% of the administered radioactive dose was excreted in urine (25%) and feces (50%) after [(3)H]11-OH-Delta(9)-THC administration. The disposition, excretion, and metabolism of [(3)H]11-OH-Delta(9)-THC appear to be similar to that previously reported after [(14)C]Delta(9)-THC administration. These findings, in conjunction with the marked psychologic high seen after 11-OH-Delta(9)-THC, suggest that in man, Delta(9)-THC, the active constituent in marihuana, is converted to 11-OH-Delta(9)-THC, which is in part responsible for the psychologic effects.

Adult↗